{"nctId":"NCT00422240","briefTitle":"Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris","startDateStruct":{"date":"2006-06-27","type":"ACTUAL"},"conditions":["Acne Vulgaris"],"count":1668,"armGroups":[{"label":"Adapalene/Benzoyl Peroxide Gel","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene/Benzoyl Peroxide"]},{"label":"Adapalene Gel, 0.1%","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene Gel, 0.1%"]},{"label":"Benzoyl Peroxide Gel 2.5%","type":"EXPERIMENTAL","interventionNames":["Drug: Benzoyl Peroxide Gel 2.5%"]},{"label":"Gel Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Gel Vehicle"]}],"interventions":[{"name":"Adapalene/Benzoyl Peroxide","otherNames":[]},{"name":"Adapalene Gel, 0.1%","otherNames":[]},{"name":"Benzoyl Peroxide Gel 2.5%","otherNames":[]},{"name":"Gel Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A clinical diagnosis of acne vulgaris with facial involvement.\n* A minimum of 20 but not more than 50 inflammatory lesions\n* A minimum of 30 but not more than 100 noninflammatory lesions\n* A score of 3 (Moderate) on the Investigator's Global Assessment Scale","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)","description":"Success rate was defined as percentage of participants who achieved \"Clear\" or \"Almost Clear\" score on the IGA scale. IGA scale consisted of 5 grades (0-4) among which 0 = Clear (Minor, residual discoloration, no erythema or induration/papulation, no oozing/crusting), 1 = Almost clear (Trace, faint pink erythema with almost no induration/papulation and no oozing/crusting), 2 = Mild (Faint pink erythema with mild induration/papulation and no oozing/crusting), 3 = Moderate (Pink-red erythema with moderate induration/papulation and there may be some oozing/crusting.), 4 = Severe (Deep/bright red erythema with severe induration/papulation with oozing/crusting). All missing values were imputed by LOCF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"19.8","spread":null},{"groupId":"OG002","value":"22.2","spread":null},{"groupId":"OG003","value":"11.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Inflammatory Lesion Count From Baseline to Week 12","description":"Change in inflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"27.0","spread":null},{"groupId":"OG002","value":"27.0","spread":null},{"groupId":"OG003","value":"27.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","spread":null},{"groupId":"OG001","value":"-14.0","spread":null},{"groupId":"OG002","value":"-16.0","spread":null},{"groupId":"OG003","value":"-10.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Noninflammatory Lesion Count From Baseline to Week 12","description":"Change in noninflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null},{"groupId":"OG001","value":"47.0","spread":null},{"groupId":"OG002","value":"46.0","spread":null},{"groupId":"OG003","value":"46.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.0","spread":null},{"groupId":"OG001","value":"-22.0","spread":null},{"groupId":"OG002","value":"-20.0","spread":null},{"groupId":"OG003","value":"-14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Inflammatory Lesion Counts at Week 12","description":"The Inflammatory Lesion Count was the sum of papules and pustules. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \\* 100. All missing values were imputed by LOCF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.33","spread":"34.678"},{"groupId":"OG001","value":"-41.68","spread":"41.855"},{"groupId":"OG002","value":"-47.61","spread":"38.415"},{"groupId":"OG003","value":"-30.23","spread":"41.661"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Noninflammatory Lesion Counts at Week 12","description":"The Noninflammatory Lesion Count was the sum of open comedones and closed comedones. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \\* 100. All missing values were imputed by LOCF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.15","spread":"35.428"},{"groupId":"OG001","value":"-40.75","spread":"40.822"},{"groupId":"OG002","value":"-37.23","spread":"39.758"},{"groupId":"OG003","value":"-23.22","spread":"48.613"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Lesion Counts at Week 12","description":"The Total Lesion Count was the sum of Inflammatory, Noninflammatory Lesion Counts, Nodules and Cysts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.97","spread":"31.966"},{"groupId":"OG001","value":"-41.29","spread":"36.133"},{"groupId":"OG002","value":"-41.23","spread":"33.794"},{"groupId":"OG003","value":"-26.06","spread":"38.714"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":415},"commonTop":["Nasopharyngitis","Dry skin"]}}}